An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200
mg of RWJ-333369 given twice daily compared with placebo in the treatment of postherpetic
neuralgia.